Open AccessJournal Article
Long-term survival.
Cho Yw,Terasaki Pi +1 more
TLDR
In transplants performed between 1971 and 1986, first cadaver donor grafts had a half-life ranging from 6.6 to 7.5 years in the period after the first year, and for patients receiving kidneys with no HLA-A,B mismatches, the average half- life was 10.1 years.Abstract:
1. In transplants performed between 1971 and 1986, first cadaver donor grafts had a half-life ranging from 6.6 to 7.5 years in the period after the first year. Second cadaver donor grafts had a half-life of 5.1 to 6.5 years. Parental donor grafts had a half-life of 9.3 to 11.8 years, whereas HLA identical sibling donor transplants had a half-life of 19.1 to 26.5 years. Siblings with no haplotype in common had an average half-life of 8.7 years. 2. Between 1971 and 1984, white recipients had an average half-life of 7.7 years, which increased to 9.3 years in 1985-1986. Black recipients' half-life decreased from 5.4 years in 1975-1976 to 3.5 years in 1985-1986. The reason for this decrease is not apparent. 3. The half-life of transplants of different recipient ages did not vary significantly. The average half-life during this period of study was 7.4 years for those younger than 21 years of age, 8.2 years for recipients 21 to 50 and 6.7 years for those older than 50. 4. In the early data, there was some evidence that the half-life of kidneys with cold ischemia below 13 hours was superior. However, in the latest period (between 1983 and 1986) the average half-life was 7.6 years for CIT below 13 hours, 7.2 years for those with 13 to 24 hours and 6.4 years for more than 24 hours. 5. For patients receiving kidneys with no HLA-A,B mismatches, the average half-life was 10.1 years. Those with A,B mismatches had a half-life of 6.7 years, and for those with no A,B antigens in common, the average half-life was 6 years. 6. In the period after 1981, the average half-life of patients with no A,B,DR mismatches was 9.1 years compared with 6.5 years for those with A,B,DR mismatches and 5.4 years for those with no A,B,DR antigens in common.read more
Citations
More filters
Journal ArticleDOI
The Tetrafigap Survey on the long-term outcome of tetraplegic spinal cord injured persons: Part III. Medical complications and associated factors
TL;DR: The medical complications of spinal cord injured persons are frequent, they are linked to biological, psychological and environmental factors, and are interrelated, therefore, seeking mid- and long-term risk factors must be given priority in order to better adapt attempts at increasing secondary prevention.
Journal ArticleDOI
The Clinical and Economic Burden of Nonadherence with Antihypertensive and Lipid-Lowering Therapy in Hypertensive Patients
Spencer B. Cherry,Joshua S. Benner,Joshua S. Benner,Mohamed A. Hussein,Simon S K Tang,Michael B. Nichol +5 more
TL;DR: Hypertensive patients taking antihypertensive and statin therapy at real-world adherence levels can be expected to receive approximately 50% of the potential benefit seen in clinical trials.
Journal ArticleDOI
Enzymatic oxidative biodegradation of nanoparticles: Mechanisms, significance and applications.
Irina I. Vlasova,Alexandr A. Kapralov,Zachary P. Michael,Seth C. Burkert,Michael R. Shurin,Alexander Star,Anna A. Shvedova,Valerian E. Kagan +7 more
TL;DR: The strategies leading to safe by design carbonaceous nanoparticles with optimized characteristics for mechanism-based targeted delivery and regulatable life-span of drugs in circulation are concluded.
Journal ArticleDOI
Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work.
Marcos de Lima,Sara S. Strom,Michael J. Keating,Hagop M. Kantarjian,Sherry Pierce,Susan O'Brien,Emil J. Freireich,Elihu H. Estey +7 more
TL;DR: Patients with potentially cured AML are likely to be able to return to work, and at least if younger do not, on average, have an increased risk of invasive cancer.
Journal ArticleDOI
Male germ cell transplantation in livestock
Jonathan R. Hill,Ina Dobrinski +1 more
TL;DR: Male germ cell transplantation is a powerful approach to study the control of spermatogenesis with the ultimate goal to enhance or suppress male fertility in livestock animals and could create an alternative to AI in areas where it is impractical.